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D
espite recent advances, the molecular and cellular mechanisms that contribute to atherosclerotic plaque instability/vulnerability are not entirely understood. Studies have found that extracellular matrix (ECM) remodeling takes place during atherosclerotic plaque progression. 1 In healthy human arteries, the endothelium resides on an ECM that is mainly composed of collagen type IV and laminin, with largely devoid of cellular fibronectin containing extra domain A (Fn-EDA). [2] [3] [4] In contrast, the ECM of atherosclerotic arteries is enriched in Fn-EDA in both humans and mice. [2] [3] [4] Fibronectin plays a pivotal role in several cellular and biological processes. 5 Fibronectin gene undergoes alternative splicing at 3 sites 6 : extra domain A (EDA), extra domain B (EDB), and the type III homologies connecting segment. 6 Fibronectin exists in 2 forms in humans and mice: (1) plasma fibronectin that lacks the alternatively spliced EDA and EDB and is synthesized by hepatocytes; (2) cellular fibronectin (cFn) that contains either the EDA and EDB or both. cFn is synthesized by fibroblasts and other cells, including endothelial cells and vascular smooth muscle cells (VSMCs). 5 Alternative splicing of EDA and EDB is developmentally regulated. Inclusion of EDA and EDB in cFn increases during embryonic development but decreases substantially after birth. 7, 8 Fn-EDA plays a role in several biological and pathological processes, including wound healing, 9 ,10 vascular hypertension, 11 and fibrotic disorders of the lung, liver, and skin. [12] [13] [14] Previously, we and others have reported that deletion of the EDA exon of the fibronectin gene reduces early atherosclerotic plaque progression, suggesting a role for Fn-EDA in progression of early atherosclerosis. [15] [16] [17] The contribution of Fn-EDA in advanced human atherosclerosis remains poorly characterized. 18 A murine study suggested that abundant Fn-EDA expression may paradoxically stabilize advanced plaques. 17 In contrast, several lines of evidence support the hypothesis that increased Fn-EDA in advanced atherosclerotic plaques may induce plaque destabilization by potentiating the TLR4 (toll-like receptor 4) innate immune signaling pathway in macrophages or other cells: (1) Fn-EDA is an endogenous ligand of TLR4 19 that colocalizes with macrophage TLR4 in human and murine atherosclerotic plaques. 16 (2) TLR4 contributes to Fn-EDA-mediated early atherosclerosis exacerbation in 5-month-old male and female Apoe −/− mice. 16 (3) Fn-EDA promotes MMP9 (matrix metalloproteinase 9) gene activity in THP-1 19 and synovial cells, 20 and MMP9 is known to induce histological features of plaque destabilization. 21 In the current study, we used aged (1-year-old) Apoe Histological features of plaque composition were studied in the innominate artery, a well-established site of plaque instability that is known to exhibit histological and gene expression characteristics similar to vulnerable human plaques. 22, 23 We found that Fn-EDA induces features of plaque destabilization in advanced lesions of the innominate artery.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Fn-EDA/TLR4 Axis Induces Histological Features of Plaque Destabilization in the Innominate Artery
Previously, we have found that Fn-EDA contributes to early atherosclerosis exacerbation both in male and female mice. 16 Because Fn-EDA-mediated early atherosclerosis exacerbation was sex independent, herein, we used only female mice to determine the contribution of Fn-EDA/TLR4 axis in advanced atherosclerotic progression. Apoe Apoe −/− mice were fed a high-fat Western diet for 44 weeks. Irrespective of the genotype, we found that ≈35% to ≈40% mice died after 36 weeks on high-fat Western diet in all the groups (Table) . The cause of premature death remains unclear. In the mice that survived up to 50 weeks of age, plasma cholesterol and triglycerides were comparable among groups (Table) . Plasma levels of proinflammatory cytokines, including IL-1β (interleukin 1 beta) and TNFα (tumor necrosis factor alpha), which are known to be elevated in atherosclerotic lesions, were similar among groups (Table) . Deletion of Fn-EDA or TLR4 in Apoe −/− mice did not affect body weight or complete blood counts (not shown), which are in agreement with previous studies. 16 We next analyzed plaque size and composition by histology (explained in Figure I Table) , suggesting that TLR4 may contribute to Fn-EDA-mediated plaque destabilization.
Fn-EDA/TLR4 Axis Promotes Apoptosis in Advanced Plaques
Cellular apoptosis is known to promote plaque necrosis in advanced lesions. 24 We quantified cellular apoptosis by terminal deoxynucleotidyl transferase deoxyuridine triphosphate (dUTP) nick end labeling method. We observed a decrease in terminal Figure 3B ). The possibility that some of the terminal deoxynucleotidyl transferase dUTP nick end labeling/CD68-positive cells could be derived from VSMCs could not be ruled out. Previous studies have shown that ≈50% of cells in advanced atherosclerotic plaques in mice and humans are derived from VSMCs. 25, 26 Together, these results suggest that ECM enriched in Fn-EDA promotes VSMC and macrophage apoptosis in advanced lesions. To determine the molecular mechanism by which Fn-EDA promotes apoptosis, we focused on TLR4. Figure 3A and 3B). Together, these results suggest that TLR4 may contribute to Fn-EDA-mediated apoptosis in advanced lesions of aged Apoe −/− mice.
Fn-EDA/TLR4 Axis Mediates MMP9 Potentiation in Macrophages
Monocytes/macrophages were present in the ECM surrounding the necrotic core ( Figure III in the online-only Data Supplement). MMPs expressed by VSMCs and monocytes/macrophages are known to degrade and remodel the ECM. Fn-EDA is known to potentiate MMP9 activity in vitro. 19 ,20 Therefore, we focused on MMP9 expression within plaques by immunohistochemistry. The percent 
Discussion
The findings of our study performed in aged Apoe −/− mice suggest that an ECM microenvironment enriched in Fn-EDA may increase the risk of plaque destabilization in advanced atherosclerotic lesions and that Fn-EDA induces plaque instability in part via a TLR4 pathway. These findings in EDA-and TLR4-deficient Apoe −/− mice may have clinical significance for the following reasons: (1) Fn-EDA is abundantly expressed in the ECM of advanced atherosclerotic plaques in humans 16, 18 ; and (2) Two clinical studies have shown a positive correlation between TLR4 expression on plaque monocytes and the clinical stages of atherosclerosis in patients with unstable angina and myocardial infarction. 27, 28 We chose to study the innominate artery of aged Apoe −/− mice to elucidate the contribution of Fn-EDA in advanced atherosclerosis because, unlike other animal models of atherosclerosis, the innominate artery mimics several histological features of vulnerable human plaques, including large necrotic cores, thin fibrous caps, and intraplaque hemorrhage. 22, 23 However, this model has some limitations because some features observed in vulnerable human plaques, such as denuded endothelium and large occlusive thrombi, are rarely present. 29, 30 Despite these limitations, there is a consensus that of all currently available murine models of atherosclerosis, the innominate artery is the most informative model to elucidate the mechanisms and factors that may contribute to increased risk of plaque destabilization.
We found that genetic deletion of Fn-EDA in 1-year-old Apoe −/− mice significantly reduced plaque size, characterized by a decreased necrotic core, reduced CD68-positive cell content, decreased VSMC and macrophage apoptosis, and absence of intraplaque hemorrhage, implicating Fn-EDA as a mediator of destabilization of advanced plaques. In contrast, although our studies were in progress, another study by Pulakazhi Venu et al 17 suggested that Fn-EDA may paradoxically promote plaque stabilization. In that study, the authors observed decreased atherosclerosis in the aortic sinus of 5-month-old Fn-EDA −/− Apoe −/− mice, a finding that is consistent with current findings. Surprisingly, however, the authors reported that the smaller atherosclerotic lesions in Fn-EDA −/− Apoe −/− mice exhibited features of plaque instability characterized by increased macrophage content, increased MMP2 and MMP9 expression, and reduced collagen gene expression. Based on these findings, the authors concluded that Fn-EDA promotes atherosclerosis but stabilizes plaque. This was a surprising finding because we have reported previously that decreased atherosclerosis in the aortic sinus of 5-month-old male and female Fn-EDA −/− Apoe −/− mice is associated with reduced macrophage content. 16 Several other studies have shown that macrophages promote atherosclerosis and that Fn-EDA is known to potentiate MMP9 expression. 19, 20, 24, 31 The explanation for the apparent discrepancies between the study by Pulakazhi Venu et al 17 in 5-month-old mice and our current results in 1-year-old mice remains unclear but could be related to the different sites of atherosclerosis and ages of the mice studied. Notably, Pulakazhi Venu et al 17 did not determine several relevant parameters of plaque destabilization, including necrotic core, apoptosis, and intraplaque hemorrhage. 17 In our opinion, the data reported herein provide novel mechanistic insights beyond the study reported by Pulakazhi Venu et al 17 for the following reasons. First, we determined the contribution of Fn-EDA in advanced lesions of the innominate artery of aged mice, a plaque instability site that mimics several histological features of vulnerable human plaques. The choice of experimental animal model is important because it is well established that the mechanisms of plaque progression governing different stages of atherosclerosis are distinct. For example, macrophage apoptosis in early atherosclerosis is protective but detrimental to advanced lesions. 32 Second, we performed a comprehensive histological analysis of plaque stability that included assessment of the necrotic area, intraplaque hemorrhage, fibrous cap thickness, and neovascularization. Third, we provide additional mechanistic insight into how Fn-EDA may contribute to plaque instability. We found that Fn-EDA promotes VSMC and macrophage apoptosis. Increased apoptosis in advanced lesions contributes to lesion size and enlargement of the necrotic core because of defective efferocytosis. 32 Fourth, we provide a molecular mechanism by which Fn-EDA may induce plaque destabilization. We found that deletion of TLR4 reduced features of plaque instability, including necrotic Our studies also suggest a mechanistic link between Fn-EDA, TLR4, and MMP9 in plaque destabilization. TLR4 contributes to outward arterial remodeling, 36 a process that involves higher MMP9 expression and excessive ECM degradation. Other studies have suggested an association between MMP9 expression and atherosclerotic plaque destabilization. 21, 37 Herein, we found that Fn-EDA/TLR4 axis promotes an increase in CD68-positive cells expressing MMP9 and increased accumulation of MMP-cleaved aggrecan (an ECM constituent) in the fibrous cap region around the necrotic core. Together, these observations suggest that the Fn-EDA/ TLR4 axis, by potentiating MMP9 activity in macrophages, may contribute to degradation and remodeling of ECM, and, thereby, increase the risk of plaque destabilization. Previously, we have shown that exogenous cFn (which contains EDA) potentiates the phosphorylation of NFκB (nuclear factor kappa B) p65 via TLR4 in macrophages. 16 Here, we found that exogenous cFn also potentiated MMP9 activity in bone marrow-derived macrophages via TLR4. Based on the studies reported herein, we propose a mechanistic model in which infiltrating CD68 monocytes/macrophages or resident macrophages interact with Fn-EDA in the ECM niche of advanced atherosclerotic lesions, potentiating MMP9 activity to degrade and remodel ECM components in the fibrous cap, thereby increasing the risk of plaque destabilization. The possibility that other MMPs, such as MMP2, may contribute to Fn-EDA/ TLR4-mediated plaque destabilization cannot be excluded. Although our studies indicate that TLR4 signaling significantly contributes to Fn-mediated plaque destabilization, it remains possible that some of the proinflammatory effects of Fn-EDA could be partially mediated by the leukocyte integrins α4β1 and α9β1, which are known to have binding sites within the EDA domain. 38 Additional complex studies will be required to determine whether disruption of Fn-EDA-integrin interactions in vivo prevents monocyte recruitment and subsequent atherosclerotic lesion progression and stability.
Our studies have some limitations. First, Fn-EDAmediated histological features of plaque destabilization were not associated with luminal thrombus, which is a characteristic feature of vulnerable human plaques. 29, 30 Notably, reproducible thrombus in the lumen has not been observed by several groups in the advanced lesions in the murine innominate artery. 21, 22 Second, the present study did not define the specific cell types that contribute to Fn-EDA-mediated plaque destabilization in advanced lesions. Additional studies using endothelial-specific and vascular smooth muscle cell-specific deletion of Fn-EDA will be required to define the cellular source of Fn-EDA that mediates plaque destabilization. Third, tissue inhibitor of metalloproteinases (TIMPs) are known to regulate MMP9 activity. We did not analyze the activity of TIMP1 and TIMP2 although in vitro studies suggest that absence of TIMP1 and TIMP2 does not enhance proteolytic autoactivation of MMP9 in macrophages, implicating the existence of other independent mechanisms that regulate MMP9. 21 In summary, our studies unequivocally support a causal connection between Fn-EDA present in advanced atherosclerotic plaques and increased MMP9 activity in macrophages that may increase the risk of plaque destabilization. These observations suggest that interventions targeting Fn-EDA may lessen plaque progression and reduce plaque destabilization.
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